1. Rutkowski B, Tylicki L. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails. J Ren Nutr 2015;25:194–200.

2. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084–2092.

3. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156–1162.

4. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5:531–548.

5. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016;67:728–741.

6. Villain C, Metzger M, Liabeuf S, et al.; CKD-REIN Study Group. Effectiveness and tolerance of renin-angiotensin system inhibitors with aging in chronic kidney disease. J Am Med Dir Assoc 2022;23:998–1004e7.

7. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl):S212–S220.

8. Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc 2019;8:e012655.

9. Humphrey TJL, James G, Wittbrodt ET, Zarzuela D, Hiemstra TF. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J 2021;14:2203–2212.

10. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project. J Am Heart Assoc 2017;6:e005428.

11. Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS One 2019;14:e0213192.

12. Riccio E, Capuano I, Buonanno P, et al. RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med 2022;9:824095.

13. Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant 2021;36:826–839.

14. Stanton BA. Regulation of Na+ and K+ transport by mineralocorticoids. Semin Nephrol 1987;7:82–90.

15. Zanella MT, Mattei E Jr, Draibe SA, Kater CE, Ajzen H. Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure. Clin Pharmacol Ther 1985;38:613–617.

16. Kaplan NM. The biosynthesis of adrenal steroids: effects of angiotensin II, adrenocorticotropin, and potassium. J Clin Invest 1965;44:2029–2039.

17. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2012;350:151–162.

18. Swartz SL, Williams GH, Hollenberg NK, Dluhy RG, Moore TJ. Primacy of the renin-angiotensin system in mediating the aldosterone response to sodium restriction. J Clin Endocrinol Metab 1980;50:1071–1074.

19. Schambelan M, Sebastian A, Biglieri EG. Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int 1980;17:89–101.

20. Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855–860.

21. Hené RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98–101.

22. Chen WG, Zhou TT, Zhou P, et al. Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease. Int J Clin Exp Pathol 2015;8:6901–6909.

23. Radloff J, Pagitz M, Andrukhova O, Oberbauer R, Burgener IA, Erben RG. Aldosterone is positively associated with circulating FGF23 levels in chronic kidney disease across four species, and may drive FGF23 secretion directly. Front Physiol 2021;12:649921.

24. Arruda JA, Batlle DC, Sehy JT, Roseman MK, Baronowski RL, Kurtzman NA. Hyperkalemia and renal insufficiency: role of selective aldosterone deficiency and tubular unresponsiveness to aldosterone. Am J Nephrol 1981;1:160–167.

25. Shiah CJ, Wu KD, Tsai DM, Liao ST, Siauw CP, Lee LS. Diagnostic value of plasma aldosterone/potassium ratio in hypoaldosteronism. J Formos Med Assoc 1995;94:248–254.

26. Adam WR. Hypothesis: a simple algorithm to distinguish between hypoaldosteronism and renal aldosterone resistance in patients with persistent hyperkalemia. Nephrology (Carlton) 2008;13:459–464.

27. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:S8–S138. 28. Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 2006;23:345–356.

29. Koo H, Lee SG, Kim JH. Evaluation of random urine sodium and potassium compensated by creatinine as possible alternative markers for 24 hours urinary sodium and potassium excretion. Ann Lab Med 2015;35:238–241.

30. West ML, Bendz O, Chen CB, et al. Development of a test to evaluate the transtubular potassium concentration gradient in the cortical collecting duct in vivo. Miner Electrolyte Metab 1986;12:226–233.

31. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.

32. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.

33. Ethier JH, Kamel KS, Magner PO, Lemann J Jr, Halperin ML. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990;15:309–315.

34. Zettle RM, West ML, Josse RG, Richardson RM, Marsden PA, Halperin ML. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes. Am J Nephrol 1987;7:360–366.

35. Mayan H, Kantor R, Farfel Z. Trans-tubular potassium gradient in patients with drug-induced hyperkalemia. Nephron 2001;89:56–61.

36. Musso C, Liakopoulos V, De Miguel R, Imperiali N, Algranati L. Transtubular potassium concentration gradient: comparison between healthy old people and chronic renal failure patients. Int Urol Nephrol 2006;38:387–390.

37. Mc Greevy C, Horan J, Jones D, Biswas K, O’Meara YM, Mulkerrin EC. A study of tubular potassium secretory capacity in older patients with hyperkalaemia. J Nutr Health Aging 2008;12:152–155.

38. Gennari FJ, Segal AS. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int 2002;62:1–9.

39. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol 2015;10:1050–1060.

40. Kovesdy CP, Appel LJ, Grams ME, et al. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. Am J Kidney Dis 2017;70:844–858.

41. Truhlář A, Deakin CD, Soar J, et al.; Cardiac arrest in special circumstances section Collaborators. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation 2015;95:148–201.

42. Weinberg JM, Appel LJ, Bakris G, et al.; African American Study of Hypertension and Kidney Disease Collaborative Research Group. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009;169:1587–1594.

43. Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol 2014;9:295–301.

44. Keilani T, Danesh FR, Schlueter WA, Molteni A, Batlle D. A sub-depressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999;33:450–457.

45. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021;99(3S):S1–S87.

46. Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl Physiol (1985) 2004;96:1406–1414.